Gastrointestinal amyloidosis most notably occurs in the liver and small intestine.
Its presentation is highly nonspecific and may include gastrointestinal bleeding,
malabsorption syndromes, and protein-losing enteropathy. Chronic gastrointestinal
dysmotility, while relatively uncommon, carries a particularly grave prognosis. In
those with amyloidosis, gastric involvement occurs in 8% of patients, with only 1%
being symptomatic.
1
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to The American Journal of MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Gastrointestinal manifestations of amyloidosis.Am J Gastroenterol. 2008; 103: 776-787
- Review article: gastrointestinal amyloidosis - clinical features, diagnosis and therapy.Aliment Pharmacol Ther. 2008; 27: 1006-1016
- Endoscopic and biopsy findings of the upper digestive tract in patients with amyloidosis.Gastrointest Endosc. 1990; 36: 10-14
Article Info
Publication History
Published online: February 19, 2020
Footnotes
Funding: None.
Conflict of Interest: None.
Authorship: All authors had access to the data and a role in writing this manuscript.
Identification
Copyright
© 2020 Elsevier Inc. All rights reserved.